Demystifying MetLife: Insights From 9 Analyst Reviews

Throughout the last three months, 9 analysts have evaluated MetLife MET, offering a diverse set of opinions from bullish to bearish.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 5 4 0 0 0
Last 30D 0 1 0 0 0
1M Ago 3 0 0 0 0
2M Ago 1 3 0 0 0
3M Ago 1 0 0 0 0

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $86.0, a high estimate of $96.00, and a low estimate of $80.00. This upward trend is evident, with the current average reflecting a 1.31% increase from the previous average price target of $84.89.

price target chart

Exploring Analyst Ratings: An In-Depth Overview

The analysis of recent analyst actions sheds light on the perception of MetLife by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Elyse Greenspan Wells Fargo Raises Overweight $86.00 $85.00
Joshua Shanker B of A Securities Lowers Buy $96.00 $99.00
Michael Ward Citigroup Raises Buy $89.00 $83.00
Suneet Kamath Jefferies Raises Buy $86.00 $83.00
Nigel Dally Morgan Stanley Raises Overweight $83.00 $82.00
Ryan Krueger Keefe, Bruyette & Woods Lowers Outperform $85.00 $86.00
Jimmy Bhullar JP Morgan Raises Overweight $86.00 $81.00
Suneet Kamath Jefferies Lowers Buy $83.00 $88.00
Kevin Heal Argus Research Raises Buy $80.00 $77.00

Key Insights:

  • Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to MetLife. This information provides a snapshot of how analysts perceive the current state of the company.
  • Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of MetLife compared to the broader market.
  • Price Targets: Analysts predict movements in price targets, offering estimates for MetLife's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into MetLife's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on MetLife analyst ratings.

Unveiling the Story Behind MetLife

MetLife is one of the largest life insurers in the us by assets and provides a variety of insurance and financial services products. The company is organized into five segments: us, Asia, Latin America, EMEA, and MetLife Holdings. The U.S. business contributes around 50% of earnings and is broken into the group benefits segment and the retirement solutions segment. The Asia segment contributes around 22% of earnings and is mainly composed of the Japan business with increasing contributions from India, China, and Bangladesh. The company also holds leading market positions in Mexico and Chile with the Latin America segment contributing around 13% of earnings. The EMEA and the MetLife segments contribute around 4% and 11% of earnings, respectively.

A Deep Dive into MetLife's Financials

Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.

Positive Revenue Trend: Examining MetLife's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.73% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: MetLife's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 5.22%, the company may face hurdles in effective cost management.

Return on Equity (ROE): MetLife's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 3.27%, the company may face hurdles in achieving optimal financial performance.

Return on Assets (ROA): MetLife's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.13%, the company may face hurdles in achieving optimal financial returns.

Debt Management: MetLife's debt-to-equity ratio surpasses industry norms, standing at 0.67. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

The Significance of Analyst Ratings Explained

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!